

Index

- Abdominal pain in Williams syndrome, 205
Adderall, 96
Adolphs, R., 239
Adrenarche in Klinefelter syndrome, 65
Alant, E., 385
Altshul-Stark, D., 90
American Association on Mental Retardation, 392
Amino acid metabolism, 298–303
Androgen-deficiency in Klinefelter syndrome, 62–64
Animals and hypothyroidism, 272–273
Anticipatory guidance and genetic counseling, 374–378
Anxiety
 and hyperarousal in fragile X syndrome, 82–83, 91–92
 in Williams syndrome, 241
Aqueductal stenosis, 141
Ashkoomoff, N. A., 231
Asperger syndrome in Turner syndrome, 27
Assistive technology, 482
Atkinson, J., 232
Attention and executive function
 congenital hypothyroidism and, 281–282, 284
 DS22q11.2 and, 178, 185–188
 fragile X syndrome and, 90–91
 Klinefelter syndrome and, 58–59
Attention deficit/hyperactivity disorder (ADHD)
 congenital hypothyroidism and, 281–282
 DS22q11.2 and, 168, 178
 fragile X syndrome and, 82, 85, 91–92
 phenylketonuria and, 301
 Williams syndrome and, 206, 241–242
Autism
 Duchenne muscular dystrophy and, 121
 fragile X syndrome and, 83–85
 interventions, 96–97
 mercury and, 351–352
 Turner syndrome and, 27
 Williams syndrome and, 242
Autoimmune thyroiditis, 22
Bagnato, S. J., 445
Bailey, D. B., 82, 91, 400, 453
Baker, K., 190
Baranek, G. T., 91
Barth syndrome, 322, 425–430
Bayley Scales of Infant Development, 277
Bearden, C. E., 177
Bechar, T., 223
Becker muscular dystrophy, 106
Behavioral characteristics
 congenital hypothyroidism, 285, 286f
 DS22q11.2 and, 452–453
 Duchenne muscular dystrophy, 120–121, 125–127
 early intervention and, 447–448
 fragile X syndrome, 82–85, 453–454
 Klinefelter syndrome, 59–60
 mental retardation and adaptive, 391–393, 403–404
 Williams syndrome, 208–210, 217, 234–240
Bellinger, D., 337
Bellugi, U., 221, 223, 225, 230, 233, 238
Belsler, R. C., 82, 87
Bender, B. G., 29
Bernard, S., 351
Bertrand, J., 220, 230
Bickel, H., 303
Billard, C., 119
Billingsley, R. L., 149, 150
Bishop, D., 224
Bjugstad, K. B., 306
Blacher, J., 407
Bleeding, gastrointestinal, 22
Boccia, M. L., 82
Boutet, I., 89
Brain development
 Duchenne muscular dystrophy and, 112–113
 fragile X syndrome and, 76–81
 inborn errors of metabolism and, 300–301, 324–326
 Klinefelter syndrome and, 49, 60–64, 64

- Brain development (cont.)
 lead poisoning and, 336–339
 manganese effect on, 353–354
 mercury effects on, 346
 neurofibromatosis and, 136–137, 141–142, 146–149
 phenylketonuria and, 300–301
 thyroid hormone and, 272
 tumors and, 147
 Turner syndrome and, 24–25
- Brewer, V. R., 145
- Bruno, E., 245
- Campbell, D., 347
- Carbohydrate metabolism disorders
 galactosemia, 310–312, 313–314t
 pyruvate dehydrogenase deficiency, 312
- Cardiovascular disorders
 Turner syndrome and, 20
 Williams syndrome and, 206, 245
- Carey Temperament Scales, 32
- Cayler cariofacial syndrome, 164
- Celiac disease in Turner syndrome, 21
- Central hypothyroidism, 270
- Central nervous system
 creatine disorders and, 321
 neurofibromatosis and, 141–142
- Chelation, 342
- Chen, T. Y., 407
- Chess, S., 234
- Child-focused practices in early intervention, 446–448
- Cholesterol biosynthesis disorders, 323
- Chromosome 22q11.2 deletion syndrome
 attention in, 168, 178
 cognitive and academic manifestations of, 170–173, 191–193
 cognitive experimentation studies, 179–188
 definition, 163–164
 diagnosis, 166, 168–170
 early intervention and special education for, 449–453
 enumeration in, 182–183
 executive function and inhibition in, 185–188
 feeding problems, 451–452
 incidence of, 164–165
 IQ in, 173–174, 450
 language skills in, 175, 176–177, 451
 magnitude estimation and mathematical reasoning in, 183–185
 memory in, 176, 177–178
 motor abilities in, 178–179, 452
 multidisciplinary assessment and service coordination, 452
 neural and genetic correlates, 188–191
 neuropsychological profile, 173–174
 physical manifestations, 165–166, 167f
 preschool services for children with, 453
 psychiatric disorders associated with, 167–170
 reading and spelling skills in, 175–176, 177
 schizophrenia and, 168, 189–191
 visual-spatial attention in, 181–182
- Chromosomes
 Duchenne muscular dystrophy abnormalities in, 106–107
 imprinting and, 11
 Klinefelter syndrome abnormalities in, 50–51
 Turner syndrome abnormalities in, 5, 6f, 7t
 Civil rights and mental retardation, 398–399
- Classroom placement, 483–484
- Cognition. *See* Neurocognition
- Concerta, 96
- Congenital hypothyroidism. *See* Hypothyroidism, congenital
- Connective tissue abnormalities and Williams syndrome, 245
- Coordination, visual-motor, 89
- Cornish, K., 85, 89
- Coyle, J. T., 304
- Creatine deficiency syndromes, 320–321
- Creswell, C., 27
- Crohn's disease, 22
- Cross, G., 85
- Cunningham, C. C., 401
- Cystathionine beta-synthase deficiency, 303–305
- Cystic hygroma, 13f
- Daniels, M., 168, 179
- Davenport, M. L., 31–32, 35, 430, 459
- Davies, W., 11
- Dental problems in Williams syndrome, 204
- Devenny, D. A., 229
- Dexedrine, 96
- Diabetes mellitus in Turner syndrome, 23
- Diagnosis
 autism, 83–84
 chromosome 22q11.2 deletion syndrome, 166, 168–170
 Duchenne muscular dystrophy, 106
 genetic counseling beyond, 378–379
 genetic counseling immediately before and after, 367–370, 374–378
 inborn errors of metabolism, 298, 299t
 interpretation by children, 382–383
 Klinefelter syndrome, 47–49
 lead poisoning, 340–341
 learning disability as a risk, not a, 422–424
 learning to talk about, 379–382
 mental retardation, 393, 395–396, 401–402
 neurofibromatosis (NF), 135–137
 prenatal genetic, 369–370
 recurrence risk and, 384–385
 and siblings of affected patients, 385–386
 Turner syndrome, 16–18, 34–36
 Williams syndrome, 206–208
- Diamond, A., 300

- Differential Ability Scales (DAS), 212, 213f, 215t
- DiGeorge, Angelo, 163
- Digit Span, 227
- Dilts, C., 239
- Division for Early Childhood of the Council for Exceptional Children, 443–444
- Dorman, C., 118–119
- Downey, J., 28
- Down syndrome
- attention deficit/hyperactivity disorder (ADHD) and, 85
 - memory and, 88
 - mental retardation and, 394, 395, 400
 - portrayed in the media, 398–399
 - prenatal diagnosis, 402
- Doyle, T. F., 235
- Drawing abilities and Williams syndrome, 230–231
- Drosophila NF-1 protein, 140
- DS2q11.2. *See* Chromosome 22q11.2 deletion syndrome
- Dubowitz, V., 118
- Duchenne, Guillaume-Benjamin-Amand, 106
- Duchenne muscular dystrophy
- academic skills in, 118–119
 - autism and, 121
 - and Becker muscular dystrophy, 106
 - behavioral characteristics, 120–121, 125–127
 - brain development and, 112–113
 - cognitive skills in, 114–117, 125–127
 - diagnosis, 106
 - discovery of, 106
 - dystrophin and, 107–108
 - gene, 106–107
 - IQ scores and, 113–114, 115–117
 - medical management of, 110–112
 - physical presentation, 108–110
 - prevalence, 105, 106
 - quality of life in older individuals with, 124–125
 - stress and, 122–123
- Due process, 487–488
- Dunst, C. J., 446
- Dykens, E. M., 90, 233, 240, 452, 463
- Dysgenesis, thyroid, 267–268
- Dyshormonogenesis, thyroid, 268–270
- Dyslexia, 149, 150
- Dystrophin, 107–108, 112–113
- Early Childhood Outcomes (ECO), 442–443
- Early intervention and early childhood special education (ECSE)
- assessment for planning and monitoring, 439, 444–445
 - child-focused practices in, 446–448
 - determining eligibility for, 439
 - family-centered approach to, 445–446
 - family stressors and, 438
 - fragile X syndrome, 455–458
 - Individualized Family Service Plan, 439–440
 - interdisciplinary models, 448–449
 - Klinefelter syndrome, 460–464
 - outcomes, 441–443
 - purpose of, 437, 464–465
 - 22q11.2 deletion syndrome, 449–453
 - recommended practices, 443–449
 - service delivery, 440–441
 - Turner syndrome, 458–460
- Early Social Communication Scales, 220
- Einfeld, S., 240
- Elastin arteriopathy in Williams syndrome, 205, 245
- Eligibility, individualized education plan, 476
- Encephalopathy, mitochondrial, 316
- Endocrinology of Klinefelter syndrome, 51–52
- Engel, P., 234
- English as a Second Language classes, 481–482
- Enumeration tasks and DS22q11.2, 182–183
- Epidemiology
- Klinefelter syndrome, 50
 - neurofibromatosis (NF), 134
- Estrogen therapy in Turner syndrome, 26
- Event-related potentials, 60–61
- Everyday Memory Questionnaire, 283–284
- Executive function. *See* Attention and executive function
- Expressive Vocabulary Test (EVT), 217–218
- Extended school year (ESY), 482–483
- Eye problems
- Turner syndrome, 21
 - Williams syndrome, 203
- Family. *See also* Parents
- centered approach to early intervention, 445–446
 - composition and mental retardation, 404–406
- Farran, E. K., 230
- Fatty acid oxidation disorders, 316–318
- Feeding problems
- DS22q11.2 deletion syndrome, 451–452
 - Turner syndrome, 21
- Feinstein, C., 168
- Fidler, D. J., 239
- Finucane, B. M., 451
- 504 plans, 486
- Fivush, R., 382
- Fluorescent in situ hybridization (FISH) studies, 5
- Fragile X syndrome
- attention deficit/hyperactivity disorder and, 82, 85, 91–92, 93–97
 - autism and, 83–85, 96–97
 - behavioral considerations in, 82–85, 453–454
 - cognitive profile, 86
 - cognitive strengths and difficulties, 86–91, 424–425
 - early intervention and special education, 455–457
 - family support and, 457–458
 - genetic and brain-level considerations, 76–81

- Fragile X syndrome (cont.)
 importance of recognizing comorbidities in, 91–92
 IQ and, 426–430
 learning to talk about, 379–382
 memory in, 88–89
 mental retardation and, 396–397
 number processing in, 90
 pharmacologic interventions, 96, 97, 454–455, 457
 physical characteristics, 73, 74f, 75–76t
 prevalence, 73
 repetitive speech in, 87–88
 social anxiety and hyperarousal in, 82–83
 speech and language in, 86–88
 tangential and perseverative language in, 87
 visual-motor coordination in, 89
- Frigerio, E., 238
 Frith, U., 432
 Frontal brain structural malformation, 141–142
 Functional behavioral assessments (FBAs), 475
 Functional disomy, 11
 Functional imaging studies of neurofibromatosis, 149–151
 Fusco, J., 407
- Gagliardi, C., 237
 Galaburda, A. M., 64
 Galactosemia, 310–312, 313–314t
 Gastroesophageal reflux (GERD), 203, 205
 Gastrointestinal disease in Turner syndrome, 21–22
 Geffner, M. E., 31–32
 Geier, D. A., 351
 Geier, M. R., 351
 General Conceptual Ability (GCA) scores, 212, 215f
 Generalized anxiety disorder (GAD), 241
 Genetic counseling
 anticipatory guidance and, 374–378
 beyond the diagnosis, 378–379
 children's interpretation of, 382–383
 collection/review of family medical history, 371
 components of, 370–374
 contracting, 371
 diagnostic process and, 368–370
 discussion and formulation of diagnostic plan, 373
 discussion of clinical suspicion and findings, 371–373
 following diagnosis of genetic disorder, 374–378
 follow-up, 378–379
 medical genetics evaluation and, 368–370
 recurrence risks and, 384–385
 referral to the medical genetics clinic for, 368
 siblings and, 385–386
 Genetic mutations
 DS22q11.2, 188–191
 Duchenne muscular dystrophy, 106–107
 fragile X syndrome, 76–81, 89
 neurofibromatosis, 137–139
 Williams syndrome, 242–248
 Gerdes, M., 450–451
 Gerner, G., 28
 Geschwind, N., 64, 463
 Glidden, L. M., 405, 406, 407
 Glutaric acidemia type I, 306–307
 Glycine encephalopathy, 318–319
 Gonadal dysgenesis, 19–20
 Good, C. D., 10
 Gopnik, A., 220
 Gosch, A., 234
 Gothelf, D., 190
 Grace, R. J., 60
 Grammatical ability in Williams syndrome, 223–224
 Grant, J., 226
 Gratton effect, 186
 Greenwood, R. S., 149
 Greer, M. K., 239
 Growth hormone, 19–21
GTF2I gene, 246–247
 Gunther, D. F., 7
 Guthrie, R., 303
- Hagerman, R., 84, 90, 454
 Harper, D. C., 121
 Hart, S. J., 25
 Hartman, D. E., 344
 Hatton, D. D., 82, 85, 91, 394, 456
 Havercamp, F., 21
 Hayes, A., 84
 Hearing loss
 in Turner syndrome, 21
 in Williams syndrome, 204
 Henry, A. E., 28
 Hepburn, S. L., 84
 Hepworth, S., 283
 Hernias, inguinal, 203
 Heyerdahl, S., 287
 Hobart, H. H., 243
 Hoehn-Saric, R., 82
 Hoffman, J. E., 232
 Homeobox genes, 9
 Homocystinuria, 303–305
 Hooper, S. R., 31–32, 91
 Hormonal factors
 in Klinefelter syndrome, 51–52, 58, 59–60, 62–64
 in Turner syndrome, 26
HSP27 gene, 246
 Hyperarousal in fragile X syndrome, 82–83
 Hypercalcemia, 203
 Hyperglycemia, nonketotic, 318–319
 Hyperphenylalaninemia (HPA), 303
 Hypersensitivity in fragile X syndrome, 82–83
 Hypersociality in Williams syndrome, 238–239

- Hypertension
 in Turner syndrome, 20
 in Williams syndrome, 205
- Hypertrophic scar formation, 23
- Hypothyroidism
 central, 270
 congenital
 attention in, 281–282
 behavior problems and, 285, 286f
 cognitive abilities, 278–284
 early diagnosis, 290
 etiologies of, 267–270
 executive function in, 284
 influence of disease and treatment-related variables, 287–289
 intelligence and, 276–278, 288–289
 language skills and, 279
 memory and, 283–284
 motor abilities and, 280–281
 neuropsychological profile in children with, 276
 phenotype-genotype correlations, 289
 physical features, 265–266
 prevalence, 265
 school achievement and, 284–285
 thyroid dysgenesis and, 267–268
 thyroid dysmorphogenesis and, 268–270
 thyroid hormone resistance and, 270
 visuospatial abilities and, 279–280
 studies
 with animals, 272–273
 with humans, 273–274
 transient, 271, 287
 in Turner syndrome, 22
- Hypotonia disorders, 321–322
- Imprinted genes, 11
- Inactivation, X, 8–9
- Inborn errors of metabolism (IEM)
 Barth syndrome, 322
 carbohydrate, 310–314
 cholesterol biosynthesis disorders, 323
 classifications, 297
 creatine deficiency syndromes, 320–321
 cystathionine beta-synthase deficiency, 303–305
 fatty acid oxidation, 316–318
 galactosemia, 310–312, 313–314t
 glutaric acidemia type I, 306–307
 hypotonia and, 321–322
 maple syrup urine disease, 305–306
 medium chain acylCoA dehydrogenase deficiency, 317–318
 methylmalonic and propionic acidemia, 308–310
 mitochondrial, 315–316
 molybdenum cofactor deficiency, 319–320
 neurotransmitter disorders, 322–323
 nonketotic hyperglycinemia, 318–319
 organic acid, 308–310
 phenylketonuria (PKU), 298–303
 protein, 298–308
 pyruvate dehydrogenase deficiency, 312
 respiratory chain disorders, 315–316
 seizures and, 318–321
 system effects of, 297
 tyrosinemia type II, 305
 urea cycle disorders, 307–308
- Inclusive education, 483–484
- Independent educational evaluations (IEEs), 475
- Individualized Education Program (IEP), 438, 471–472
 annual goals, 478
 assistive technology and, 482
 Child Study Teams, 474
 classroom placement, 483–484
 current performance section, 477–478
 definition, 473
 due process and, 487–488
 eligibility criteria, 476
 evaluation process, 474–476
 extended school year and, 482–483
 history of, 472–473
 identification of children with disabilities and, 473–474
 lack of available resources for, 485–486
 for limited English speakers, 481–482
 parent role in, 479, 485
 504 plans and, 486
 preparing classroom peers and, 484
 related services, 480–481
 role of parents in, 479
 self-contained classroom placements, 485
 specialized training for staff, 481
 testing areas, 474–476
 timeline, 488–489
 transition from secondary to postsecondary education, 483
 writing, 477
- Individualized Family Service Plan (IFSP), 438–439, 439–440
- Individuals with Disabilities Education Act (IDEA), 416, 437, 471–473. *See also* Early intervention and early childhood special education (ECSE)
- Inflammatory bowel disease in Turner syndrome, 22
- Inhibition in DS22q11.2, 185–188
- Intelligence and IQ. *See also* Mental retardation
 congenital hypothyroidism and, 276–278, 288–289
 cystathionine beta-synthase deficiency and, 303–304
 DS22q11.2, 173–174, 450
 Duchenne muscular dystrophy, 113–114, 115–117
 fragile X syndrome, 86
 galactosemia and, 311

- Intelligence and IQ. *See also* Mental retardation (cont.)
- Klinefelter syndrome, 56
 - lead poisoning effects on, 339
 - maple syrup urine disease and, 305–306
 - mental retardation classification and, 391–392
 - neurofibromatosis, 143
 - nonverbal learning disability and, 425–430
 - Turner syndrome, 25
 - Williams syndrome, 210–212, 246–247
- Interdisciplinary models in early intervention, 448
- Interventions
- Duchenne muscular dystrophy, 125–127
 - fragile X syndrome, 92–97
 - learning disability, 431–432
 - planning and monitoring, 439
- Itti, E., 62
- Jackendoff, R., 219
- Johnson, M. H., 173
- Jordan, H., 232
- Judgment of Line Orientation test, 145–146
- Jugular vein, 9
- Karayorgou, M., 187
- Karmiloff-Smith, A., 218, 226, 236
- Karyotype abnormalities
- Klinefelter syndrome, 50–51
 - Turner syndrome, 5, 6f, 7t
- Kaufman Brief Intelligence Test (KBIT) and Williams syndrome, 210–212, 213t, 214f
- Kemper, M. B., 90
- Keysor, C. S., 82
- Kiley-Brabeck, K., 168, 179, 187
- Klein, B. P., 226
- Klein-Tasman, B. P., 235, 242
- Klinefelter, H., 47
- Klinefelter syndrome
- academic abilities in, 56–57, 419
 - adrenarche in, 65
 - attention and executive function in, 58–59
 - brain development in, 49, 60–64
 - diagnosis and identification, 47–49
 - early intervention and special education, 460–464
 - endocrinology of, 51–52
 - epidemiology, 50
 - hormonal factors influencing development in, 62–64
 - IQ in, 56
 - karyotypes and genetic mechanisms, 50–51
 - language abilities in, 57–58
 - microcephaly in, 61–62
 - motor function in, 52–55
 - neurocognition in, 55–59
 - physical characteristics of, 47–49, 52, 53–55f
 - prevalence, 47, 50
 - social development in, 59–60
 - testosterone levels in, 51–52, 58, 59–60, 62–64
- Koeberl, D. D., 32
- Kogan, C. S., 89
- Kooistra, L., 280
- Kozma, C., 174, 192
- Kraemer, U., 337
- Kuntsi, J., 27
- Lactic acidosis, 316
- Laing, E., 220
- Lajiness-O'Neill, R. R., 176
- Landau, B., 221, 222, 232
- Language and speech abilities
- congenital hypothyroidism and, 279
 - DS22q11.2 and, 175, 176–177, 451
 - fragile X syndrome and, 86–87
 - Klinefelter syndrome and, 57–58
 - relations between cognitive abilities and, 225–227
 - tangential and perseverative, 87
 - Williams syndrome and, 208–210, 219–227
- Laws, G., 224
- Lead poisoning
- diagnosis, 340–341
 - government regulations and, 342–343
 - lessons learned from, 356
 - neurodevelopmental effects of, 338–339
 - socioeconomic status and, 337–338
 - treatment, 342–343
 - vulnerability of children to, 336–338
- Learning and academic achievement
- congenital hypothyroidism and, 284–285
 - DS22q11.2 and, 170–173, 191–193
 - Duchenne muscular dystrophy and, 118–119
 - Klinefelter syndrome and, 462–464
 - neurofibromatosis and, 143–145, 150–151, 156–157
- Learning disability (LD)
- biological basis of, 418
 - classification of, 416–417
 - definitions, 415–418
 - generalizing group findings to individuals with, 424–425
 - genetic disorders as models of, 418–422
 - intervention and identification, 431–432
 - IQ and, 425–430
 - nonverbal, 27, 29t, 415, 425–431
 - as a risk, not a diagnosis, 422–424
- Lenhard, W., 400
- LeRoux, C., 305
- Lesniak-Karpiak, K., 31, 82, 88
- Levitin, D. J., 233, 241
- Levy, Y., 223
- Leyfer, O. T., 240
- Liebowitz, D., 118
- LIMK1* gene, 247
- Liver
- enzymes in Turner syndrome, 22

- methylmalonic and propionic acidemia and, 309
 transplantation in urea cycle disorders, 307–308
 Lopez, S., 407
 Lunskey, Y., 406
 Lymphatic development in Turner syndrome, 9–10
 Lymphedema, 14f, 15, 18, 20
 Lyon, M. F., 9
- Macrocephaly in neurofibromatosis, 148–149
 Magnetic resonance imaging
 of congenital hypothyroidism, 274
 of glutaric acidemia type I, 306–307
 of maple syrup urine disease, 306
 of neurofibromatosis, 136–137, 146–147, 147–148, 149–151
 of phenylketonuria, 301
 Magnitude estimation and DS22q11.2, 183–185
 Manganese poisoning, 352–356
 Maple syrup urine disease (MSUD), 305–306
 Masataka, N., 219, 220
 Mathematics skills
 Barth syndrome and, 322
 DS22q11.2 and, 180–181, 183–185
 fragile X syndrome and, 90
 Turner syndrome and, 28
 Mazzocco, M. M. M., 28, 82, 88, 90, 144
 McCauley, E., 30–31
 McDonald-McGinn, D. M., 451, 452
 McLeod, D. R., 82
 McMillan, D. L., 404
 McWilliam, R. A., 445, 448
 Mediation, 487–488
 Medium chain acylCoA dehydrogenase deficiency, 317–318
 Meltzoff, A. N., 220
 Memory
 congenital hypothyroidism and, 283–284
 DS22q11.2 and, 176, 177–178
 Duchenne muscular dystrophy and, 115
 fragile X syndrome and, 88–89
 Klinefelter syndrome and, 464
 Williams syndrome and, 226–229
 Mental retardation. *See also* Intelligence and IQ
 adaptation during childhood, 402–403
 adaptive behaviors and, 391–393, 408
 behavioral phenotypes, 403–404
 civil rights and, 398–399
 cystathionine beta-synthase deficiency and, 303–304
 deinstitutionalization and, 397
 diagnosis of, 399–400, 401–402
 diagnostic and etiological challenges, 393
 dimensions of classification, 396–397
 diverse etiology, 393–394
 family characteristics and resources, 404–406
 fragile X syndrome and, 81, 82
 heterogeneity of functioning and, 391–393
 hypotonia and, 321–322
 mainstreaming and inclusion and, 398
 medical treatment and, 397–398
 methylmalonic and propionic acidemia and, 309–310
 mild, 403
 moderate/severe/profound, 403
 multicultural issues and, 407
 neonatal screening for, 399–400
 phenylketonuria and, 300
 prenatal screening for, 399
 range in functioning of those with, 400–401
 seizures and, 324
 social support for, 406
 stigmatization of, 395
 uncertainty of prognosis in, 395–396
 Mercury
 autism and, 351–352
 clinical effects of, 346, 347–352
 elemental, 345–346
 fetal effects of, 350–351
 high level effects of, 347–349
 historical uses and misuses of, 344
 methyl-, 346–352
 moderate to low level effects of, 349–351
 Merrick, John, 133–134
 Mervis, C. B., 219, 223, 225, 226, 228, 230, 231, 235, 238
 Metabolic syndrome in Turner syndrome, 23
 Methylmalonic and propionic acidemia, 308–310
 Methylmercury, 346–352
 Methylphenidate/Ritalin, 96
 Meyer-Lindenberg, A., 222, 239, 242, 247
 Microcephaly
 Klinefelter syndrome, 61–62
 Williams syndrome, 203
 Miller, L. J., 82
 Mirrett, P. L., 456, 457
 Mishkin, J. V., 25
 Mismatch negativity (MMN) signal, 187
 Mitochondrial disorders, 315–316
 Molybdenum cofactor deficiency, 319–320
 Morris, C. A., 247
 Mosaicism, 7, 9–10, 81
 Motor function
 congenital hypothyroidism and, 280–281
 DS22q11.2 and, 178–179, 452
 Klinefelter syndrome and, 52–55
 Williams syndrome and, 204–205
 Mullen Scales of Early Learning (MSEL), 30, 213t, 217
 Multicultural issues and mental retardation, 407
 Multiple schwannomatosis. *See* Neurofibromatosis (NF)
 Munir, F., 85, 88
 Murphy, D. G., 28

- Murphy, M. M., 90
- Musicality and Williams syndrome, 233–234
- Myelin abnormalities, 300–301, 324–326
- Neisworth, J. T., 445
- NEO Five Factor Inventory, 405
- Netley, C., 55, 60–61
- Neurocognition
- congenital hypothyroidism and, 278–284
 - DS22q11.2 and, 170–173, 179–188
 - Duchenne muscular dystrophy and, 114–117, 125–127
 - fragile X syndrome and, 86–91
 - galactosemia and, 311
 - Klinefelter syndrome and, 55–59
 - neurofibromatosis and, 142–146
 - relations between language and, 225–227
 - Turner syndrome and, 10, 23–30
 - Williams syndrome and, 208–210, 227–234, 248–249
- Neurofibromas, 139–140
- Neurofibromatosis (NF)
- brain structure/function correlates, 146–147
 - brain tumors and, 147
 - clinical case studies, 151–156
 - clinical features, 135–136
 - definition, 133–134
 - diagnosis, 135–137
 - epidemiology, 134
 - functional imaging studies of, 149–151
 - genetic counseling and, 375–377
 - influences on central nervous system morphology, 141–142
 - intellectual functioning in, 143
 - learning and academic achievement profile in, 143–145, 150–151, 156–157, 419, 420–422
 - macrocephaly and, 148–149
 - MR hyperintensities and, 147–148
 - neurocognitive status of children with, 142–146
 - NF-1 gene, 137–139
 - systemic impact of, 139–140
 - visual-spatial processing in, 145–146
- Neuroimaging
- functional, 62
 - structural, 61–62
 - Williams syndrome, 204
- Neuropsychological profiles of DS22q11.2, 173–174
- Neurotoxic metals
- lead, 336–344
 - manganese, 352–356
 - mercury, 344–352
- Neurotransmitter disorders, 322–323
- No Child Left Behind Act, 441–442, 473
- Nonketotic hyperglycinemia, 318–319
- Nonverbal learning disability (NLD), 415
- etiologies and discrepant profiles, 425–431
 - Turner syndrome and, 27, 29t
- Number processing in fragile X syndrome, 90
- Occupational therapy
- Duchenne muscular dystrophy, 111–112
 - fragile X syndrome, 95
- O'Neill, M. J., 11
- Online Mendelian Inheritance of Man (OMIM), 11, 368
- Opperman, S., 385
- Organic acid metabolism disorders
- methylmalonic and propionic acidemia, 308–310
- Orthodontic problems in Turner syndrome, 14f, 22–23
- Osborne, L. R., 247
- Otitis media, chronic, 203–204
- Ovarian function in Turner syndrome, 10
- Pagani, B., 232
- Pagon, R. A., 239
- Pankau, R., 234
- Parents. *See also* Family
- due process for, 487–488
 - role in IEPs, 479, 485
- Parker, S. K., 352
- Pattern construction and Williams syndrome, 231–232
- Pavakis, S. G., 316
- Peabody Picture Vocabulary Test (PPVT-III), 214f, 217
- Peers, classroom, 484
- Percutaneous umbilical blood sampling, 369–370
- Peregrine, E., 225
- Peroxisomal disorders, 322
- Personality. *See* Behavioral characteristics
- Pharmacologic therapy
- Duchenne muscular dystrophy, 110–112
 - fragile X syndrome, 96, 97, 454–455, 457
- Phenylketonuria (PKU), 298–303, 418
- Philofsky, A., 84
- Physical presentation
- chromosome 22q11.2 deletion syndrome, 165–166, 167f
 - Duchenne muscular dystrophy, 108–110
 - fragile X syndrome, 73–76
 - Klinefelter syndrome, 47–49, 52, 53–55f
 - Turner syndrome, 12–17, 35f, 36
 - Williams syndrome, 201, 202f
- Picker, J. D., 304
- 504 plans, 486
- Pléh, C., 227
- Plesa-Skwerer, D., 236
- Plomin, R., 420, 423, 424
- Posttraumatic stress disorder (PTSD) and fragile X syndrome, 83
- Prader-Willi syndrome, 233
- Pragmatics in Williams syndrome, 224–225
- Prepulse inhibition (PPI), 187
- Preschool services
- DS22q11.2 and, 453

- Prevalence rates
 chromosome 22q11.2 deletion syndrome, 164–165
 Duchenne muscular dystrophy, 105, 106
 fragile X syndrome, 73
 Klinefelter syndrome, 47, 50
 Turner syndrome, 7–8
- Propionic and methylmalonic acidemia, 308–310
- Protein metabolism disorders
 cystathionine beta-synthase deficiency, 303–305
 glutaric acidemia type I, 306–307
 maple syrup urine disease, 305–306
 phenylketonuria, 298–303
 tyrosinemia type II, 305
 urea cycle disorders, 307–308
- Pseudoautosomal region (PAR), 3
- Psychiatric disorders associated with DS22q11.2, 167–170
- Psychosocial phenotypic expression
 congenital hypothyroidism, 274–276
 DS22q11.2, 452–453
 interventions for fragile X syndrome, 93–94
 Klinefelter syndrome, 59–60
 Turner syndrome, 23–24, 30–33
 Williams syndrome, 234–242
- Puberty
 adrenarche in, 65
 Klinefelter syndrome and, 47–49, 65
 Turner syndrome and, 19–20
- Pyruvate dehydrogenase deficiency, 312
- Quality of life and Duchenne muscular dystrophy, 124–125
- Quigley, C. A., 31–32
- Rabensteiner, B., 234
 Raefski, A. S., 11
 Ratcliffe, S., 55, 61
 Recurrence risks, 384–385
 Religious beliefs, 405
 Renal malformations in Turner syndrome, 20
 Respiratory chain disorders, 315–316
 Rey-Osterreith Complex Figure Test, 59
 Robbins, I., 83
 Roberts, J., 82, 90, 91
 Robinson, B. F., 226, 228
 Rogers, S. J., 84
 Rogol, A., 461
 Role play, 95
 Ross, J., 459, 460
 Ross, M. T., 10, 26–27, 33, 82
 Rourke, B. P., 27
 Rovet, J., 28, 55, 459, 463
 Rowe, M. L., 221
 Rutter, M., 337
- Sadler, L. S., 245
 Salbenblatt, J. A., 60
- Samango-Sprouse, C., 461
 Sarimski, K., 239
 Savendahl, L., 35
 Scales of Independent Behavior-Revised (SIB-R), 216f, 217
 Schizophrenia and DS22q11.2, 168, 189–191
 School achievement. *See* Learning and academic achievement
 Schoolcraft, S. A., 405, 406
 Schowalter, J. E., 28
 Schrimsher, G. W., 146
 Seizure disorders, 318–321, 324
 manganese and, 355
 Self-contained classroom placement, 485
 Semantic development and Williams syndrome, 221–223
 Sener, R. N., 305
 Shaffer, J. W., 25
 Shapiro, J., 407
 Shen, D., 61
 Shiloh, S., 367
 Short stature homeobox-containing (SHOX) gene
 Klinefelter syndrome and, 52
 Turner syndrome and, 9, 16–17, 18–19
 Shprintzen, Robert, 163, 174
 Siblings of affected patients, 385–386, 404–405
 Single photon emission computed tomography (SPECT), 62
 Skin disorders in Turner syndrome, 23
 Skinner, M., 82
 Skotko, B. G., 399
 Skuse, D. H., 11, 27
 Smith-Lemi-Opitz syndrome (SLOS), 323, 418
 Smith-Magenis syndrome, 239–240
 Sobin, C., 168, 179, 187
 Social support and mental retardation, 406
 Socioeconomic status
 of families with mentally retarded children, 405–406
 lead poisoning and, 337–338
 Solot, C. B., 175, 177
 Speech and language abilities. *See* Language and speech abilities
 Spinal meningocoels, 141
 Spinal muscular atrophy (SMA), 114
 Stature
 Klinefelter syndrome and, 47–49
 Turner syndrome and, 9, 16–17, 18–19
 Williams syndrome and, 203
 Stiers, P., 192
 Stiles, J., 231
 Strabismus
 Turner syndrome, 21
 Williams syndrome, 203
 Stress and Duchenne muscular dystrophy, 122–123
 Stroke-like episodes, 316

- Structural neuroimaging, 61–62
 Sudhalter, V., 82, 87, 394
 Sullivan, K., 236, 237
 Supravalvar aortic stenosis (SVAS), 205
 Swillen, A., 30, 168
 Symons, F. J., 456
- Tager-Flusberg, H., 236, 237
 Tang, C. S., 407
 Temple, C. M., 223
 Tercyak, K., 383
 Test for Reception of Grammar (TROG), 218
 Testicular failure in Klinefelter syndrome, 47–49
 Test of Relational Concepts (TRC), 218
 Test of Visuomotor Integration, 230
 Testosterone levels and Klinefelter syndrome, 51–52, 58, 59–60, 62–64
 Thomas, A., 234
 Thyroid. *See also* Hypothyroidism
 disease in Turner syndrome, 22
 dysgenesis, 267–268
 dysharmonogenesis, 268–270
 hormone
 brain development and, 272
 resistance, 270–271
 Timeline, IEP, 488–489
 Toddler Turner Study Group, 31–32
 Tomc, S. A., 234
 Transient hypothyroidism, 271
 Transition from secondary to postsecondary education, 483
 Trivette, C. M., 446
 Tumors, brain, 147
 Turk, J., 83, 85
 Turner syndrome
 brain imaging in, 24–25
 cardiovascular malformations and hypertension in, 20
 comprehensive assessment strategies in, 33–34
 definition, 3–5
 diabetes mellitus in, 23
 diagnosis in adulthood, 16
 diagnosis in childhood, 15–18
 early identification enhancement, 34–36
 early intervention and special education, 458–460
 functional disomy and, 11
 gastrointestinal disease in, 21–22
 gonadal dysgenesis in, 19–20
 hearing loss in, 21
 heterogeneity of expression in, 32–33
 imprinting and, 11
 karyotype abnormalities, 5, 6f, 7t
 key physical findings, 12–17
 learning disability and, 419
 lymphatics in, 9–10
 lymphedema in, 14f, 15, 18, 20
 medical issues associated with, 18–30
 neurocognition in, 10, 23–30
 neurocognitive manifestations in early childhood, 29–30
 neurocognitive manifestations in school-age children and adolescents, 25–28, 29t
 orthodontic problems in, 14f, 22–23
 ovarian function in, 10
 pathophysiology, 8–10
 physical characteristics in, 3–5, 35f, 36
 prenatal diagnosis, 13, 18
 prevalence of, 7–8
 psychosocial manifestations of, 23–24, 30–33
 renal malformations in, 20
 short stature and, 18–19
 SHOX gene and, 9, 16–17, 18–19
 skin disorders in, 23
 stature in, 9
 strabismus in, 21
 x-linked recessive disorders and, 11
 Tyrosinemia type II, 305
- Ungerleider, L. G., 25
 Urea cycle disorders, 307–308
 Urinary tract malformations in Williams syndrome, 205–206
 Uttal, D. H., 424
- Van Leishout, C. F. M., 234
 Vicari, S., 219, 227
 Vignos, P. J., 118
 Vineland Social-Emotional Early Scales, 32
 Visual aids, 95, 482
 Visual-motor coordination in fragile X syndrome, 89
 Visual-spatial impairment
 congenital hypothyroidism and, 279–280
 DS22q11.2 and, 181–182
 neurofibromatosis and, 137, 144–146
 Williams syndrome and, 229–233
 Volterra, V., 223
 Von Arnim, G., 234
 Von Recklinghausen, Friedrich Daniel, 133
- Walker, S. O., 420, 423, 424
 Walsh, V., 222
 Wang, P. P., 174, 177
 Warwick, M. M., 62
 Wassink, T. H., 27
 White, S. M., 234
 Williams syndrome
 attention deficit/hyperactivity disorder and, 206, 241–242
 autism spectrum disorder and, 242
 cardiovascular disease and, 245
 definition, 199
 deleted genes expressed in the brain, 247–248
 deletion length, 246
 drawing abilities and, 230–231

- early diagnosis, 206–208
 - early language and communicative development
 - in, 219–221
 - experimental studies of personality in, 235–239
 - genetics and genotype-phenotype correlations in,
 - 242–243
 - as a genomic disorder, 243
 - intelligence in, 210–212, 246–247
 - language, cognition, personality, and behavior in,
 - 208–210
 - medical problems and therapeutic
 - recommendations, 201, 203–206
 - memory in, 226–229
 - musicality in, 233–234
 - neurocognition in, 208–210, 227–234, 248–249
 - pattern construction and, 231–232
 - physical features, 201, 202f
 - prevalence of symptoms of, 200–201t
 - problem behaviors in, 239–240
 - psychopathology and, 240–242
 - questionnaire studies of personality and
 - temperament, 234–235
 - relations between language and cognitive abilities
 - in, 225–227
 - semantic development, 221–223
 - short deletions, 246–247
 - spatial cognition in, 229–230
 - standardized assessments and, 210–219
 - variability in phenotype, 243–245
- Williams Syndrome Cognitive Profile (WSCP), 214
- Winneke, G., 337
- Wolery, M., 447
- Woodhead, M., 83
- Woodin, M. F., 177
- Worden, D. K., 118
- Wu, J. Y., 121
-
- X-inactivation, 8–9
- X-linked recessive disorders, 11
-
- Yap, S., 304
- Yorifuji, T., 27
-
- Zackai, E., 451
- Zukowski, A., 218, 222

